BRPI0721664A8 - vm23 e vm24, dois peptídeos de escorpião que bloqueiam canais de potássio de linfócitos-t humanos(sub-tipo kv1.3) com alta seletividade e diminuem as respostas de dth invivo em ratos - Google Patents

vm23 e vm24, dois peptídeos de escorpião que bloqueiam canais de potássio de linfócitos-t humanos(sub-tipo kv1.3) com alta seletividade e diminuem as respostas de dth invivo em ratos Download PDF

Info

Publication number
BRPI0721664A8
BRPI0721664A8 BRPI0721664A BRPI0721664A BRPI0721664A8 BR PI0721664 A8 BRPI0721664 A8 BR PI0721664A8 BR PI0721664 A BRPI0721664 A BR PI0721664A BR PI0721664 A BRPI0721664 A BR PI0721664A BR PI0721664 A8 BRPI0721664 A8 BR PI0721664A8
Authority
BR
Brazil
Prior art keywords
potassium channels
peptides
dth
rats
human
Prior art date
Application number
BRPI0721664A
Other languages
English (en)
Inventor
Vicente Ferreira Batista Cesar
Gurrola-Briones Georgina
Panyl György
Domingos Possani Postay Lourival
Gáspár Rezsö
Patricia Salas-Castillo Saida
S Varga Zoltán
Original Assignee
Univ Mexico Nac Autonoma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Mexico Nac Autonoma filed Critical Univ Mexico Nac Autonoma
Publication of BRPI0721664A2 publication Critical patent/BRPI0721664A2/pt
Publication of BRPI0721664A8 publication Critical patent/BRPI0721664A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9493—Immunosupressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Insects & Arthropods (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)

Abstract

vm23 e vm24, dois peptídeos de escorpião que bloqueiam canais de potássio de linfocitos-t humanos (sub-tipo kv1.3) com alta seletividade e diminuem as resposta de dth n vivo em ratos. canais de potássio kvi.3 são conhecidos por estarem envolvidos em doenças imu- nológicas e na rejeição de implantes. se descrevem aqui peptídeos capazes de bloquear com alta afinidade e especificidade canais de potássio kvl.3, suas composições farmacêuticas e métodos para utilização como bloqueador de canais de potássio kvl.3, tratamento de várias condições imunológicas e aplicações de diagnóstico. também são apresentados mé- 10 todos para suas sínteses químicas e correcta formação estrutural. estes peptídeos (vm23 e vm24) correspondem a componentes protéicos isolados do veneno do escorpião mexicano vaejovis mexicanus smithi. vm23 e vm24 se ligam a canais hkvl.3 de forma quase irrever- sível, possuindo um valor de kd na ordem de 3 picomolares quando aplicados em linfócitos humanos in vitro. vm24 foi quimicamente sintetizado e usado em experimentos in vivo com ratos exitosamente sensibilizados (resposta dth). nenhuma das formas, nativas e sintéticas de vm24, é tóxica para camundongos quando injetados com doses relativamente altas (tes- tados até 10,000 microgramas por quilograma de peso corporal de camundongo). estes peptídeos (vm24 e vm23), e seus análogos funcionais equivalentes com pelo menos 83% de identidade sequencial, são moléculas biologicamente ativas e fortes candidatos para o tratamento de várias condições imunolágicas e para aplicações de diagnóstico.
BRPI0721664A 2007-05-14 2007-05-14 vm23 e vm24, dois peptídeos de escorpião que bloqueiam canais de potássio de linfócitos-t humanos(sub-tipo kv1.3) com alta seletividade e diminuem as respostas de dth invivo em ratos BRPI0721664A8 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2007/001544 WO2008139243A1 (en) 2007-05-14 2007-05-14 Vm23 and vm24, two scorpion peptides that block human t-lymphocyte potassium channels (sub-type kv1.3) with high selectivity and decrease the in vivo dth-responses in rats

Publications (2)

Publication Number Publication Date
BRPI0721664A2 BRPI0721664A2 (pt) 2013-01-22
BRPI0721664A8 true BRPI0721664A8 (pt) 2019-01-22

Family

ID=38882810

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0721664A BRPI0721664A8 (pt) 2007-05-14 2007-05-14 vm23 e vm24, dois peptídeos de escorpião que bloqueiam canais de potássio de linfócitos-t humanos(sub-tipo kv1.3) com alta seletividade e diminuem as respostas de dth invivo em ratos

Country Status (17)

Country Link
US (1) US8394770B2 (pt)
EP (1) EP2158213B1 (pt)
JP (1) JP5249319B2 (pt)
KR (1) KR101524517B1 (pt)
CN (1) CN101796069B (pt)
AT (1) ATE537185T1 (pt)
AU (1) AU2007353147B2 (pt)
BR (1) BRPI0721664A8 (pt)
CA (1) CA2686216C (pt)
DK (1) DK2158213T3 (pt)
EA (1) EA020131B1 (pt)
ES (1) ES2379500T3 (pt)
IL (1) IL202113A (pt)
MX (1) MX2009012092A (pt)
PT (1) PT2158213E (pt)
WO (1) WO2008139243A1 (pt)
ZA (1) ZA200907909B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1931806B1 (en) 2005-10-07 2011-10-05 California Institute Of Technology Pkr activation via hybridization chain reaction
EP2155770B1 (en) 2007-05-16 2013-10-16 California Institute of Technology A versatile nucleic acid hairpin motif for programming biomolecular self-assembly pathways
EP2229473A4 (en) 2007-12-07 2011-02-02 Steven A Goldstein IDENTIFICATION OF TOXIN LIGANDS
US9834439B2 (en) 2010-07-20 2017-12-05 California Institute Of Technology Biomolecular self-assembly
US8962241B2 (en) * 2010-07-20 2015-02-24 California Institute Of Technology Triggered molecular geometry based bioimaging probes
US8924325B1 (en) * 2011-02-08 2014-12-30 Lockheed Martin Corporation Computerized target hostility determination and countermeasure
US9856472B2 (en) 2013-07-01 2018-01-02 California Institute Of Technology Small conditional RNAs
GB201408135D0 (en) * 2014-05-08 2014-06-25 Conogenetix Biosciences Gmbh Kv1.3 potassium channel antagonists
US10246496B2 (en) * 2014-08-15 2019-04-02 La Trobe University Potassium channel blockers and use thereof in the treatment of autoimmune diseases
CA3029625A1 (en) 2016-07-05 2018-01-11 California Institute Of Technology Fractional initiator hybridization chain reaction
IL264831B (en) 2016-08-30 2022-09-01 California Inst Of Techn Immunohistochemistry by hybridization chain reaction
CN110357950B (zh) * 2019-07-29 2023-04-25 武汉大学 酸性氨基酸扫描法设计的免疫抑制多肽及应用
EP4284925A1 (en) 2021-01-26 2023-12-06 California Institute of Technology Allosteric conditional guide rnas for cell-selective regulation of crispr/cas

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5494895A (en) * 1993-07-22 1996-02-27 Merck & Co., Inc. Scorpion peptide margatoxin with immunosuppressant activity
ATE307829T1 (de) 1996-12-26 2005-11-15 Suntory Ltd Skorpion-spezifische neuropeptide
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents

Also Published As

Publication number Publication date
CN101796069A (zh) 2010-08-04
CA2686216A1 (en) 2008-11-20
IL202113A0 (en) 2010-06-16
ATE537185T1 (de) 2011-12-15
CA2686216C (en) 2016-04-12
JP2010528988A (ja) 2010-08-26
IL202113A (en) 2013-01-31
BRPI0721664A2 (pt) 2013-01-22
PT2158213E (pt) 2012-03-27
CN101796069B (zh) 2014-02-19
US8394770B2 (en) 2013-03-12
EA020131B1 (ru) 2014-08-29
DK2158213T3 (da) 2012-04-10
WO2008139243A1 (en) 2008-11-20
AU2007353147A1 (en) 2008-11-20
EP2158213A1 (en) 2010-03-03
MX2009012092A (es) 2010-02-12
ES2379500T3 (es) 2012-04-26
ZA200907909B (en) 2010-07-28
EA200901530A1 (ru) 2011-08-30
KR101524517B1 (ko) 2015-06-10
KR20100023867A (ko) 2010-03-04
JP5249319B2 (ja) 2013-07-31
EP2158213B1 (en) 2011-12-14
AU2007353147B2 (en) 2014-04-03
US20110059064A1 (en) 2011-03-10

Similar Documents

Publication Publication Date Title
BRPI0721664A8 (pt) vm23 e vm24, dois peptídeos de escorpião que bloqueiam canais de potássio de linfócitos-t humanos(sub-tipo kv1.3) com alta seletividade e diminuem as respostas de dth invivo em ratos
Loughnan et al. Identification of a novel class of nicotinic receptor antagonists: dimeric conotoxins VxXIIA, VxXIIB, and VxXIIC from Conus vexillum
BRPI0414062A (pt) uso de ciclosporinas midificadas para o tratamento de distúrbios por hcv
BR0212756A (pt) Molécula de anticorpo tendo especificidade para kdr humano, variante da molécula de anticorpo, composto, sequência de dna, vetor, célula hospedeira, processo para a produção da molécula de anticorpo, composição terapêutica ou diagnóstica, e, uso da molécula de anticorpo
Pant et al. Acute toxicity of bisphenol A in rats
BRPI0411982A (pt) glicano de aperfeiçoamento de terapia
AR056104A1 (es) Compuesto de la forma polimorfica 2 de [3-(4-metoxi-2-metil-fenil)-2, 5-dimetil-pirazolo[1, 5-a]pirimidin-7-il]-[(s)-1-(3-metil-[1, 2, 4]oxadiazol-5-il)propil]-amina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento de un trastorno relacionado con n
BRPI0516825A (pt) inibição da protease ns3-ns4a do vìrus da hepatite c (vhc)
BR9813373A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente
BR0314052A (pt) Imidazolpiridinas e métodos para sua fabricação e uso
BRPI0519148A2 (pt) inibidores de homodimerizaÇço de myd88
BRPI0607043A2 (pt) lacosamida para terapia de adição
BR122019016211B8 (pt) composto, composição farmacêutica, uso do composto e processo para a fabricação do mesmo
BRPI0409739A (pt) composto, composição farmacêutica, uso de composto, e, método para o tratamento de uma doença ou de um distúrbio
López‐Vera et al. Novel α‐conotoxins from Conus spurius and the α‐conotoxin EI share high‐affinity potentiation and low‐affinity inhibition of nicotinic acetylcholine receptors
EP1690870A4 (en) PEPTIDE MARKER FOR ALZHEIMER'S DISEASE
Hattori et al. Sensitive determination of phenothiazines in body fluids by gas chromatography with surface ionization detection
BRPI0511305A (pt) método de aliviar um granuloma anular ou sarcóide, artigo manufaturado e uso de um antagonista de lfa-1
BRPI0815595B8 (pt) composição antifúngica para administração oral, que é autoemulsificante em contato com uma fase aquosa, seu uso e produto farmacêutico
Beydoun et al. Chronic immune-mediated demyelinating polyneuropathy in the setting of cetuximab treatment
BR0212917A (pt) Método para tratamento de infecção de vìrus da hepatite c em pacientes que não responderam a tratamento
Hattori et al. Determination of diphenylmethane antihistaminic drugs and their analogues in body fluids by gas chromatography with surface ionization detection
DE602008004556D1 (de) Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin
BR112022002309A2 (pt) Conjugado e usos do mesmo
Turner et al. Structural basis for α-conotoxin potency and selectivity

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL